Nana Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nana Dong has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Bo Yu
Department of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China
1 shared publication Fan Yang
Department of Cardiology The Second Affiliated Hospital of Harbin Medical University Harbin Province Heilongjiang China
1 shared publication- Feiyuan Han
Department of Cardiology The Second Affiliated Hospital of Harbin Medical University Harbin Province Heilongjiang China
1 shared publication - Hui-Bin Liu
Department of Pharmacy, the Second Affiliated Hospital of Harbin Medical University, Harbin, China
1 shared publication - Jinwei Tian
Department Of Cardiology, The Second Affiliated Hospital Of Harbin Medical University, Harbin, China
1 shared publication Li Meng
Department of Cardiology The Second Affiliated Hospital of Harbin Medical University Harbin Province Heilongjiang China
1 shared publication
Latest Publications
- Open Access
- 18 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (4) , e038175
Association of Circulating Phenylacetylglutamine With Multi‐Vessel Coronary Disease Severity and Outcomes in ST‐Segment–Elevation Myocardial Infarction
Background: There is a lack of evidence regarding the association between plasma phenylacetylglutamine levels and lesion severity and clinical prognosis in patients with ST‐segment elevation myocardial infarction (STEMI) with multivessel coronary disease (MVCD). This study aims to investigate the potential of phenylacetylglutamine as a biomarker for major adverse cardiovascular events (MACEs) of patients with STEMI and MVCD. Methods and Results: Clinical data and blood samples were collected from 631 patients with STEMI and MVCD, who underwent primary percutaneous coronary intervention. Quantitative coronary angiography analysis was performed using the QAngio XA 7.3 system. Plasma phenylacetylglutamine concentrations were measured by rapid resolution liquid chromatography quadrupole time‐of‐flight mass spectrometry. Among a total of 631 patients, median plasma phenylacetylglutamine level was 3.8 (2.1–6.8) μmol/L and the cumulative MACE rate at follow‐up was 12%. Plasma phenylacetylglutamine levels of patients with MACE were significantly higher than patients without MACE. We employed restricted cubic spline, Kaplan–Meier curves, and Cox proportional hazard models to explore the association between plasma phenylacetylglutamine and prognosis of patients with STEMI and MVCD. Per SD, an increment in phenylacetylglutamine was associated with a 24% higher risk of complexity lesion. Higher phenylacetylglutamine level was an independent predictor of MACEs (hazard ratio [HR], 2.76 [95% CI, 1.62–4.72]). A novel prognostic scoring system was established by combining phenylacetylglutamine levels with the synergy between percutaneous coronary intervention with Taxus and cardiac surgery score, with higher scores significantly increasing the risk of MACEs (HR, 4.01 [95% CI, 2.04–7.89]). Conclusions: Phenylacetylglutamine levels were associated with lesion complexity and prognosis, may serve as a novel biomarker in patients with STEMI and MVCD.
- 18 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (4) , e038175
Open AccessAssociation of Circulating Phenylacetylglutamine With Multi‐Vessel Coronary Disease Severity and Outcomes in ST‐Segment–Elevation Myocardial Infarction
Background: There is a lack of evidence regarding the association between plasma phenylacetylglutamine levels and lesion severity and clinical prognosis in patients with ST‐segment elevation myocardial infarction (STEMI) with multivessel coronary disease (MVCD). This study aims to investigate the potential of phenylacetylglutamine as a biomarker for major adverse cardiovascular events (MACEs) of patients with STEMI and MVCD. Methods and Results: Clinical data and blood samples were collected from 631 patients with STEMI and MVCD, who underwent primary percutaneous coronary intervention. Quantitative coronary angiography analysis was performed using the QAngio XA 7.3 system. Plasma phenylacetylglutamine concentrations were measured by rapid resolution liquid chromatography quadrupole time‐of‐flight mass spectrometry. Among a total of 631 patients, median plasma phenylacetylglutamine level was 3.8 (2.1–6.8) μmol/L and the cumulative MACE rate at follow‐up was 12%. Plasma phenylacetylglutamine levels of patients with MACE were significantly higher than patients without MACE. We employed restricted cubic spline, Kaplan–Meier curves, and Cox proportional hazard models to explore the association between plasma phenylacetylglutamine and prognosis of patients with STEMI and MVCD. Per SD, an increment in phenylacetylglutamine was associated with a 24% higher risk of complexity lesion. Higher phenylacetylglutamine level was an independent predictor of MACEs (hazard ratio [HR], 2.76 [95% CI, 1.62–4.72]). A novel prognostic scoring system was established by combining phenylacetylglutamine levels with the synergy between percutaneous coronary intervention with Taxus and cardiac surgery score, with higher scores significantly increasing the risk of MACEs (HR, 4.01 [95% CI, 2.04–7.89]). Conclusions: Phenylacetylglutamine levels were associated with lesion complexity and prognosis, may serve as a novel biomarker in patients with STEMI and MVCD.